The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna laid out sales expectations for the coming year on Monday that were below even the much-diminished Wall Street ...

Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at a ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...